Company intelligence / Profile preview

Verrow Pharmaceuticals

Lenexa, Kansas, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Verrow Pharmaceuticals developed preclinical-stage proprietary cyclodextrin-enabled formulations designed to reduce acute kidney injury from medical interventions, especially contrast agents. After Ligand Pharmaceuticals acquired the company in January 2018 for $2M plus earn-outs, the program was integrated into Ligand's Captisol-enabled diagnostics pipeline focused on safer diagnostic imaging agents[7][8][11].

Therapeutic areas: Nephrology
Modalities: Small moleculeCyclodextrin-enabled agents
Industry: Biotech

Partnerships

Ligand Pharmaceuticals (acquirer and platform partner)

Beyond the preview

Go deeper on Verrow Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verrow Pharmaceuticals.

Explore the full profile